These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 24767819)

  • 1. Structure-activity relationship study, target identification, and pharmacological characterization of a small molecular IL-12/23 inhibitor, APY0201.
    Hayakawa N; Noguchi M; Takeshita S; Eviryanti A; Seki Y; Nishio H; Yokoyama R; Noguchi M; Shuto M; Shima Y; Kuribayashi K; Kageyama S; Eda H; Suzuki M; Hatta T; Iemura S; Natsume T; Tanabe I; Nakagawa R; Shiozaki M; Sakurai K; Shoji M; Andou A; Yamamoto T
    Bioorg Med Chem; 2014 Jun; 22(11):3021-9. PubMed ID: 24767819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling.
    Cai X; Xu Y; Cheung AK; Tomlinson RC; Alcázar-Román A; Murphy L; Billich A; Zhang B; Feng Y; Klumpp M; Rondeau JM; Fazal AN; Wilson CJ; Myer V; Joberty G; Bouwmeester T; Labow MA; Finan PM; Porter JA; Ploegh HL; Baird D; De Camilli P; Tallarico JA; Huang Q
    Chem Biol; 2013 Jul; 20(7):912-21. PubMed ID: 23890009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Three Orthogonal Assays Suitable for the Identification and Qualification of PIKfyve Inhibitors.
    Fogarty K; Kashem M; Bauer A; Bernardino A; Brennan D; Cook B; Farrow N; Molinaro T; Nelson R
    Assay Drug Dev Technol; 2017 Jul; 15(5):210-219. PubMed ID: 28723271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of c-Rel DNA binding is critical for the anti-inflammatory effects of novel PIKfyve inhibitor.
    Terajima M; Kaneko-Kobayashi Y; Nakamura N; Yuri M; Hiramoto M; Naitou M; Hattori K; Yokota H; Mizuhara H; Higashi Y
    Eur J Pharmacol; 2016 Jun; 780():93-105. PubMed ID: 27001378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of interleukin-12 in the induction of mucosal inflammation and abrogation of regulatory T cell function in chronic experimental colitis.
    Liu Z; Geboes K; Heremans H; Overbergh L; Mathieu C; Rutgeerts P; Ceuppens JL
    Eur J Immunol; 2001 May; 31(5):1550-60. PubMed ID: 11465113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
    Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
    Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sphingosine-1-phosphate differently regulates the cytokine production of IL-12, IL-23 and IL-27 in activated murine bone marrow derived dendritic cells.
    Schaper K; Kietzmann M; Bäumer W
    Mol Immunol; 2014 May; 59(1):10-8. PubMed ID: 24434636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice.
    Elson CO; Cong Y; Weaver CT; Schoeb TR; McClanahan TK; Fick RB; Kastelein RA
    Gastroenterology; 2007 Jun; 132(7):2359-70. PubMed ID: 17570211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacophore guided discovery of small-molecule interleukin 15 inhibitors.
    Żyżyńska-Granica B; Trzaskowski B; Niewieczerzał S; Filipek S; Zegrocka-Stendel O; Dutkiewicz M; Krzeczyński P; Kowalewska M; Koziak K
    Eur J Med Chem; 2017 Aug; 136():543-547. PubMed ID: 28535470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting sorting nexin 10 improves mouse colitis via inhibiting PIKfyve-mediated TBK1/c-Rel signaling activation.
    Bao W; Liu X; You Y; Hou H; Wang X; Zhang S; Li H; Feng G; Cao X; Jiang H; Zheng M; Shen X
    Pharmacol Res; 2021 Jul; 169():105679. PubMed ID: 34010669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 7-hydroxyfrullanolide, a sesquiterpene lactone, inhibits pro-inflammatory cytokine production from immune cells and is orally efficacious in animal models of inflammation.
    Fonseca LC; Dadarkar SS; Lobo AS; Suthar AC; Chauhan VS; Chandrababu S; Sharma SD; Dagia NM; Padigaru M
    Eur J Pharmacol; 2010 Oct; 644(1-3):220-9. PubMed ID: 20621086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effects of triptolide on interleukin-10 gene-deficient mice with colitis.
    Wei X; Gong J; Zhu J; Niu L; Zhu W; Li N; Li J
    Int Immunopharmacol; 2008 Dec; 8(13-14):1808-12. PubMed ID: 18804190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
    J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of highly potent and selective type I B-Raf kinase inhibitors.
    Wang X; Berger DM; Salaski EJ; Torres N; Hu Y; Levin JI; Powell D; Wojciechowicz D; Collins K; Frommer E
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6571-4. PubMed ID: 19854649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ArPIKfyve homomeric and heteromeric interactions scaffold PIKfyve and Sac3 in a complex to promote PIKfyve activity and functionality.
    Sbrissa D; Ikonomov OC; Fenner H; Shisheva A
    J Mol Biol; 2008 Dec; 384(4):766-79. PubMed ID: 18950639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12.
    Duchmann R; Schmitt E; Knolle P; Meyer zum Büschenfelde KH; Neurath M
    Eur J Immunol; 1996 Apr; 26(4):934-8. PubMed ID: 8625991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and characterization of a novel 7-aminopyrazolo[1,5-a]pyrimidine analog as a potent hepatitis C virus inhibitor.
    Hwang JY; Windisch MP; Jo S; Kim K; Kong S; Kim HC; Kim S; Kim H; Lee ME; Kim Y; Choi J; Park DS; Park E; Kwon J; Nam J; Ahn S; Cechetto J; Kim J; Liuzzi M; No Z; Lee J
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7297-301. PubMed ID: 23159569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor.
    Das J; Chen P; Norris D; Padmanabha R; Lin J; Moquin RV; Shen Z; Cook LS; Doweyko AM; Pitt S; Pang S; Shen DR; Fang Q; de Fex HF; McIntyre KW; Shuster DJ; Gillooly KM; Behnia K; Schieven GL; Wityak J; Barrish JC
    J Med Chem; 2006 Nov; 49(23):6819-32. PubMed ID: 17154512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease.
    Nakase H; Okazaki K; Tabata Y; Chiba T
    J Gastroenterol; 2003 Mar; 38 Suppl 15():59-62. PubMed ID: 12698874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and pharmacological characterization of a novel small molecule inhibitor of phosphatidylinositol-5-phosphate 4-kinase, type II, beta.
    Voss MD; Czechtizky W; Li Z; Rudolph C; Petry S; Brummerhop H; Langer T; Schiffer A; Schaefer HL
    Biochem Biophys Res Commun; 2014 Jul; 449(3):327-31. PubMed ID: 24845568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.